The Company today provides a trading update for the financial year ended 31 December 2019.
Unaudited revenues for the full year increased by 24% to approximately £3.8m (2018: £3.0m). TMT® sales and royalties accounted for approximately £2.8m (2018: £2.2m), reflecting a greater than 28% year on year growth in that underlying business, driven both by increased sales of TMT® and the launch of TMTpro™ in June 2019. We have also delivered the highest ever number of Biomarker Services projects with revenues showing a healthy growth of 24%, despite some delays to receipt of samples in the fourth quarter. Looking forward, the Board is pleased to report that signed Biomarker Services purchase orders worth over £0.7m have been carried over into the first quarter of 2020.